These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

698 related items for PubMed ID: 11998550

  • 21. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
    Ladewski LA, Belknap SM, Nebeker JR, Sartor O, Lyons EA, Kuzel TC, Tallman MS, Raisch DW, Auerbach AR, Schumock GT, Kwaan HC, Bennett CL.
    J Clin Oncol; 2003 Oct 15; 21(20):3859-66. PubMed ID: 14551305
    [Abstract] [Full Text] [Related]

  • 22. Use of a database computer program to identify trends in reporting of adverse drug reactions.
    Johnston PE, Morrow JD, Branch RA.
    Am J Hosp Pharm; 1990 Jun 15; 47(6):1321-7. PubMed ID: 2368725
    [Abstract] [Full Text] [Related]

  • 23. Patient reporting of adverse drug reactions: useful information for pain management?
    Jarernsiripornkul N, Krska J, Richards RM, Capps PA.
    Eur J Pain; 2003 Jun 15; 7(3):219-24. PubMed ID: 12725844
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Pharmacy-coordinated program that encourages physician reporting of adverse drug reactions.
    Gilroy GW, Scollins MJ, Gay CA, Harry DJ, Giannuzzi DF.
    Am J Hosp Pharm; 1990 Jun 15; 47(6):1327-33. PubMed ID: 2368726
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers.
    Halperin EC, Hutchison P, Barrier RC.
    Int J Radiat Oncol Biol Phys; 2004 Aug 01; 59(5):1477-83. PubMed ID: 15275735
    [Abstract] [Full Text] [Related]

  • 30. National adverse drug reaction surveillance. 1986.
    Faich GA, Dreis M, Tomita D.
    Arch Intern Med; 1988 Apr 01; 148(4):785-7. PubMed ID: 3355297
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Clinical pharmacy services, pharmacy staffing, and adverse drug reactions in United States hospitals.
    Bond CA, Raehl CL.
    Pharmacotherapy; 2006 Jun 01; 26(6):735-47. PubMed ID: 16716127
    [Abstract] [Full Text] [Related]

  • 33. Multidisciplinary adverse drug reaction surveillance program.
    Prosser TR, Kamysz PL.
    Am J Hosp Pharm; 1990 Jun 01; 47(6):1334-9. PubMed ID: 2368727
    [Abstract] [Full Text] [Related]

  • 34. [Analysis of drug safety information using large-scale adverse drug reactions database].
    Morikawa K.
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2011 Jun 01; (129):1-26. PubMed ID: 22259840
    [Abstract] [Full Text] [Related]

  • 35. Paediatric adverse drug reaction reporting: understanding and future directions.
    Carleton BC, Smith MA, Gelin MN, Heathcote SC.
    Can J Clin Pharmacol; 2007 Jun 01; 14(1):e45-57. PubMed ID: 17297195
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP, Salas M, Delzell E.
    J Clin Pharmacol; 2007 Sep 01; 47(9):1074-86. PubMed ID: 17766697
    [Abstract] [Full Text] [Related]

  • 39. Preventing adverse drug reactions in the general population.
    Pezalla E.
    Manag Care Interface; 2005 Oct 01; 18(10):49-52. PubMed ID: 16265935
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.